Trial Profile
PILOT MULTICENTER OPEN STUDY TO EVALUATE EFFICACY AND TOLERABILITY OF PEG-INTERFERON ALFA-2A IN PATIENTS WITH ANTI-HBE POSITIVE CHRONIC HEPATITIS B WHO PRESENT RESIDUAL VIREMIA OR VIROLOGICAL REBOUND DURING NUCLEOS(T)IDE ANALOGUE TREATMENT.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2014
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms SPEACH-B
- 05 Aug 2011 New trial record